文献速递类风湿关节炎其他结缔组织病

靶向治疗对类风湿关节炎相关间质性肺病肺功能影响的系统评价与荟萃分析

Effect of targeted therapies on pulmonary function in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.
PubMed 文献 · RMD Open · 2026-03-19

该系统评价与荟萃分析纳入18项观察性研究共958例RA-ILD患者,评估bDMARDs和tsDMARDs对肺功能的影响。汇总分析显示FVC和DLCO均无显著变化,提示靶向药物可能稳定肺功能,各药物间无显著差异。

要点

  • bDMARDs和tsDMARDs在RA-ILD中总体稳定肺功能,FVC和DLCO无显著变化。
  • 汇总分析显示各靶向药物之间对肺功能的影响无显著差异。
  • 常见ILD类型为UIP(48%)和NSIP(40%),研究以观察性为主。

核心结论

  • bDMARDs和tsDMARDs在RA-ILD中似乎可稳定肺功能,各药物间无显著差异。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed和Cochrane数据库至2025年,纳入对照试验和观察性研究。
  • 纳入符合1987 ACR或2010 ACR/EULAR标准的RA患者,报告bDMARD或tsDMARD治疗后PFT或HRCT纵向变化的研究。
  • 共纳入18项观察性研究,958例患者,平均年龄65岁,57%为女性。

主要发现

  • 最常见的ILD类型为普通型间质性肺炎(48%)和非特异性间质性肺炎(40%)。
  • 数据覆盖利妥昔单抗(6项研究)、阿巴西普(4项)、JAK抑制剂(4项)、TNF抑制剂(1项)和托珠单抗(1项)。
  • 汇总分析显示FVC无显著总体变化(平均差-0.85%,95%CI -2.40至0.71;p=0.29)。
  • 汇总分析显示DLCO无显著总体变化(+0.79,95%CI -0.30至1.88;p=0.16)。

关键数值与推荐

  • FVC平均差-0.85%(95%CI -2.40至0.71;p=0.29),无统计学显著性。
  • DLCO平均差+0.79(95%CI -0.30至1.88;p=0.16),无统计学显著性。

临床怎么用

  • 对于RA-ILD患者,bDMARDs和tsDMARDs可能不会导致肺功能显著恶化,可考虑用于控制关节病变。
  • 治疗期间仍需监测肺功能(FVC、DLCO)和HRCT,因证据主要来自观察性研究。

局限性

  • 仅纳入观察性研究,缺乏随机对照试验证据。
  • 部分药物研究数量少(如TNF抑制剂和托珠单抗各仅1项),汇总分析受限。
  • 未报告HRCT结局的汇总分析,需进一步前瞻性研究整合PFT和HRCT终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Interstitial lung disease (ILD) is a serious extra-articular manifestation of rheumatoid arthritis (RA) associated with increased morbidity and mortality. The pulmonary safety of biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) in RA-associated ILD (RA-ILD) remains uncertain. This systematic review and meta-analysis aimed to assess the effect of bDMARDs and tsDMARDs on ILD progression in RA, focusing on pulmonary function test (PFT) parameters-forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO)-and, when available, high-resolution computed tomography (HRCT) outcomes. METHODS: PubMed and Cochrane databases were searched up to 2025 for controlled trials and observational studies, including patients with RA fulfilling the 1987 ACR or 2010 ACR/EULAR criteria. Studies reporting longitudinal changes in PFTs or HRCT after bDMARD or tsDMARD treatment were included. Meta-analyses were conducted using the inverse variance method (RevMan V.5.4.1) for pooled estimates of FVC and DLCO. RESULTS: 18 observational studies including 958 patients (mean age 65 years; 57% female) were analysed. The most frequent ILD patterns were usual interstitial pneumonia (48%) and nonspecific interstitial pneumonia (40%). Data were available for rituximab (six studies), abatacept (4), JAK inhibitors (4), tumour necrosis factor (TNF) inhibitors (1) and tocilizumab (1). Pooled analysis showed no significant overall change in FVC (mean difference -0.85%, 95% CI -2.40 to 0.71; p=0.29) or DLCO (+0.79, 95% CI -0.30 to 1.88; p=0.16). CONCLUSION: bDMARDs and tsDMARDs appear to stabilise pulmonary function in RA-ILD, without significant differences between agents. Further prospective studies integrating PFT and HRCT endpoints are needed to better define their pulmonary safety and long-term effects.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Hilliquin S, Vismara E, Berlengiero V, et al. Effect of targeted therapies on pulmonary function in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. RMD Open. 2026. PMID: 41856563. doi:10.1136/rmdopen-2025-006640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。